SelSA-1, a novel HDAC inhibitor demonstrates enhanced chemotherapeutic potential by redox modulation

Abstract excerpt

Abstract Colorectal cancer (CRC) is a multistep disorder resulting from genetic and epigenetic genome changes. It is the third most common malignancy in developed nations accounting for roughly 600,000 deaths annually. Persistent gut inflammation, as observed in inflammatory bowel disease (IBD), is a key risk factor for CRC development. From an epigenetic viewpoint, the pharmacological inhibition of HDACs using...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cholinesterase and Neurodegenerative Diseases
• Share to Histone Deacetylase Inhibitors Research
• Share to Peptidase Inhibition and Analysis